Cambridge Enterprise, the commercialisation unit of Cambridge University, has announced the institution could earn up to £10.7m ($17.6m) from the $95m sale of medtech BlueGnome to US biotech Illumina. The university has already made £7.7m from the deal, but another £3m could be earned if milestones are met by BlueGnome. The proceeds from the deal…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
